EPHX2 and Hypertension: In line with the observations that increased EET bioavailability by sEH inhibition provides beneficial cardiovascular and renal effects, several sEH inhibitors have been developed and tested for anti-hypertensive effects in multiple models of hypertension including angiotensin (ANG II)-dependent hypertension (Imig et al., 2002, 2005; Zhao et al., 2004; Loch et al., 2007; Manhiani et al., 2009).